Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triple HIV combo for children approved under PEPFAR

Executive Summary

The first triple-combination drug for treating HIV-infected children under the age of 12 years receives tentative approval from FDA Aug. 13 as part of the President's Emergency Plan for AIDS Relief. Approved as a 505 (b)(2) NDA, the twice-daily dissolvable tablet from Cipla combines lamivudine (GlaxoSmithKline's Epivir), stavudine (Bristol-Myers Squibb's Zerit) and nevirapine (Boehringer Ingelheim's Viramune). The tablet formulation makes the drug suitable for use in regions with high temperatures and high humidity and enables treatment of children weighing as little as 5 kg, Division of Antiviral Products Director Debra Birnkrant notes. FDA also gives tentative approval under PEPFAR for nevirapine tablets to be used with antiretrovirals for treating HIV-1...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS048706

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel